Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

The Food and Drug Administration approved Ozempic for treating patients with ... with diabetes have chronic kidney disease. Both type 1 and type 2 diabetes can cause kidney disease, the agency ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney ... more than 1,000 non-dialysis CKD charts shows nephrologists were turned ...

A new study published in JAMA Ophthalmology reveals that weight loss drugs like Ozempic and similar medications could cause three potentially blinding eye conditions. The research identified ...

GLP-1 agonist medications ... dose of 2.0 mg weekly. Common side effects include nausea, vomiting, diarrhea, and constipation. Consult your healthcare provider or the Ozempic medication guide ...

By Dani Blum Some people who take drugs like Ozempic have noticed a surprising but welcome side effect: They drink less. A paper published Wednesday offers the strongest evidence yet that this is ...

Earlier animal trials had shown how the glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide (Wegovy, Ozempic ... for weight reduction reach 2.4 mg/week," the researchers noted, adding ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

The maintenance dose of Ozempic for weight loss is usually 1.0 mg per week. Some individuals may require an increase to 2.0 mg if recommended by their healthcare provider. Always adhere to the ...

Some people using GLP-1 drugs like Ozempic for weight loss have a problem: Eggs are suddenly expensive and hard to find. Eggs aren't just big with fitness fans and Gaston from "Beauty and the Beast." ...